Pathology: non squamous - mNSCLC - L1 - all population;
non squamous - mNSCLC - L1 - all population | ||
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 | ||
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel | 1 | T1 |
bevacizumab plus carboplatin and paclitaxel | 0 | T0 |